Founded Year
2001Stage
IPO | IPOTotal Raised
$100.84MDate of IPO
5/10/2006About Novacea
Novacea is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including AsentarTM, which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.
Loading...
Loading...
Latest Novacea News
May 16, 2016
Join SI Premium – FREE Before the open, Novacea, Inc. (Nasdaq: NOVC ) announced that it priced its initial public offering of 6,250,000 shares of its common stock at a price to the public of $6.50 per share, which was below the $11-$13 range the company had expected. All of the shares of common stock are being offered by the Company. The shares are expected to open on the Nasdaq National Market today under the symbol "NOVC. " Bear, Stearns & Co. Inc. and Cowen and Company, LLC acted as joint book-running managers with Pacific Growth Equities, LLC and HSBC Securities (USA) Inc. as co-managers. Novacea has granted to the underwriters a 30-day option to purchase up to an additional 937,500 shares at the initial public offering price to cover over-allotments, if any. Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Novacea's in-licensed product development programs include three clinical-stage oncology product candidates. The company has one product candidate, DN-101, which is in a Phase 3 clinical trial for prostate cancer and a second product candidate, vinorelbine oral, which is expected to enter into a registration trial in late 2006 for the treatment of metastatic breast cancer. Novacea's third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for the treatment of glioblastoma multiforme. You May Also Be Interested In
Novacea Frequently Asked Questions (FAQ)
When was Novacea founded?
Novacea was founded in 2001.
Where is Novacea's headquarters?
Novacea's headquarters is located at 400 Oyster Point Boulevard, South San Francisco.
What is Novacea's latest funding round?
Novacea's latest funding round is IPO.
How much did Novacea raise?
Novacea raised a total of $100.84M.
Who are the investors of Novacea?
Investors of Novacea include Versant Ventures, Domain Associates, ProQuest Investments, Sofinnova Ventures, New Enterprise Associates and 3 more.
Who are Novacea's competitors?
Competitors of Novacea include Gelesis, PDS Biotechnology, CureDM, Mast Therapeutics, Celator Pharmaceuticals and 7 more.
Loading...
Compare Novacea to Competitors
Pivotal BioSciences, Inc. is a company focused on the development and commercialization of cancer therapies.
Kaperio is a biopharmaceutical company focused on cardiovascular disease.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
VidaGene,Inc., is a biopharmaceutical company that aims to develop pharmaceuticals based on modulation of the vitamin D receptor (VDR). VidaGene seeks to develop entirely new VDR modulators for large pharmaceutical markets such as cancer-related thrombosis, osteoporosis and psoriasis.
Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Loading...